

# WP 3 Developing methods to assess patient reported outcome of mHealth

**Francesco Petracca, CERGAS Bocconi**

AIES 2019

Pisa, October 3, 2019



# Outline

1. Content and goals of the WP
2. One step back...definitions and rationale
3. SR preliminary results
4. Conclusions and next steps

# Content and goals of the WP *Tasks*

- TASK 1: To review and map outcomes and methodologies for the assessment of mHealth applications
- TASK 2: To test the scientific validity and relevance of the framework for the assessment of mHealth apps
- TASK 3: Policy recommendations

# Background

**mHealth:** “Use of mobile devices – such as mobile phones, patient monitoring devices, PDAs, and wireless devices – for medical and public health practice” (GOe, 2015)

## Mobile medical apps:


- “Mobile apps (including accessories or attachments) available on mobile platforms that have a therapeutic or diagnostic intended purpose” - no apps aiming at disease prevention, health promotion, pregnancy assessment (Ruth Moshi, 2018)
- “Medical devices that are mobile apps, meet the definition of a medical device and can transform a platform into a regulated medical device” (FDA)

## Overall WP3 rationale

- Plenty of app development, but massive need for support in guiding adoption and diffusion
- Need to take into account the specificities of these technologies that need to be handled differently than we have handled any technology so far

# Research objective

To develop and test/validate a framework for the assessment of mHealth apps, taking into account specific app features



Source: WHO, 2016

# Previous contributions

**Original review:** Nasi, Cucciniello and Guerrazzi, The Performance of mHealth in Cancer Supportive Care: A Research Agenda, Journal of Medical Internet Research 2015;17(2):e9

---

JOURNAL OF MEDICAL INTERNET RESEARCH

Nasi et al

Original Paper

## The Performance of mHealth in Cancer Supportive Care: A Research Agenda

---

Greta Nasi<sup>1,2\*</sup>, PhD; Maria Cucciniello<sup>1,3\*</sup>, PhD; Claudia Guerrazzi<sup>4\*</sup>

<sup>1</sup>Department of Policy Analysis and Public Management, Bocconi University, Milano, Italy

<sup>2</sup>Public Management and Policy Department, SDA Bocconi School of Management, Milano, Italy

<sup>3</sup>Center for Research in Health and Social Care Management (CeRGAS), Bocconi University, Milan, Italy

<sup>4</sup>Department of Health Services Administration, School of Health Professions, University of Alabama at Birmingham, Birmingham, AL, United States

\*all authors contributed equally

**Corresponding Author:**

Greta Nasi, PhD

Public Management and Policy Department

SDA Bocconi School of Management

2nd Fl.

Via Bocconi 8

Milano, 20136

Italy

Phone: 39 025836 ext 6222

Fax: 39 0258362508

Email: [greta.nasi@unibocconi.it](mailto:greta.nasi@unibocconi.it)

# Previous contributions

## Letters

### RESEARCH LETTER

#### Characteristics of Digital Health Studies Registered in ClinicalTrials.gov

Digital health is the application of software or hardware, often using mobile smartphone or sensor technologies to improve patient or population health and health care delivery.<sup>1</sup> In contrast to drugs and traditional medical devices, which have



Invited Commentary

strict regulatory guidelines on safety and efficacy, the clinical evidence generation

for digital health tools may be motivated by other factors, including adoption, utilization, and value, that may influence study design and quality. The landscape of clinical evidence underlying digital health interventions has not been well characterized.<sup>2,3</sup> We sought to evaluate the characteristics of digital health studies registered in ClinicalTrials.gov.

Whether results will drive substantial clinical adoption is unknown because small studies, even if randomized, are unlikely to be significantly powered to demonstrate meaningful treatment effects. Although the pipeline of digital health studies appears to be promising, these factors could limit their ability to yield a high level of evidence, demonstrate value, or motivate stakeholder adoption.

# *Systematic review of mobile health apps performance*

## COMED Review

**Review aim:** to identify all performance dimensions of mobile health apps that have been addressed by empirical studies in some of the main chronic NCDs

### **Specific research questions:**

- What are characteristics of the included studies in terms of study design and features of mHealth apps?
- What are the outcome findings of studies?
- Which are the performance dimensions, clinical and non-clinical, on which mobile health apps have proved to have a significant impact on?



# *Systematic review of mobile health apps performance*

## COMED Review – Inclusion criteria

1. **Study design:** Empirical studies with a prospective design and a quantitative approach
2. **Participants:** Studies examining population groups with the 4 main types of chronic diseases, as identified by the World Health Organization (WHO): “four main types of non-communicable chronic diseases are cardiovascular diseases, cancers, chronic respiratory diseases (such as chronic obstructed pulmonary disease and asthma) and diabetes” (WHO, 2016)
3. **Interventions:** Of interest are all mobile interventions that focus on improving health using an app device - specialized software downloaded onto mobile devices that support their utilization such as mobile phones and tablets
4. **Outcomes:** All relevant performance dimensions and their relative outcomes were included
5. **Publication date:** Studies published from 2008 (iPhone App store and Android App store were both launched on 2008) to present (November 6, 2018)
6. **Timing, setting and language:** No restrictions based on the timing and type of setting of the retrieved studies. Only articles reported in English and Italian were included


# *Systematic review of mobile health apps performance*

## COMED Review – Exclusion criteria

- Studies with **no control group**
- Studies assessing **mHealth app's feasibility and usability only**, with not even a preliminary evaluation of app efficacy
- Different study designs or publication type
- Apps not accessible to patients

# Systematic review of mobile health apps performance


## PRISMA FLOWCHART




# Descriptive and study design characteristics of included studies

# *Trend of published studies*


## Number of studies per year



# *Number of studies by Chronic NCD*



# Sample size of the studies



Min=18  
Average= 113  
Max=376

	Cardiovascular diseases	Cancer	Chronic respiratory disease	Diabetes
N	13	7	12	26
Average sample size	92	127	121	120


# Further study characteristics

Length	Number of studies	%
Up to 1 month	4	7.0%
1-3 months	21	36.8%
4-6 months	10	35.1%
7-12 months	12	21.1%

- No innovative **study designs** (85.2% RCTs)
- Only few of the identified apps are currently available on common stores



# *Device used in the studies*



# Taxonomies for BCT and outcome findings

# Outcomes taxonomy used to classify the studies



Journal of Clinical Epidemiology 96 (2018) 84–92

Journal of  
Clinical  
Epidemiology

Paula R. Williamson

## ORIGINAL ARTICLE

A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery

Susanna Dodd<sup>a</sup>, Mike Clarke<sup>b</sup>, Lorne Becker<sup>c</sup>, Chris Mavergames<sup>d</sup>, Rebecca Fish<sup>e</sup>,  
Paula R. Williamson<sup>a,\*</sup>

<sup>a</sup>MRC North West Hub for Trials Methodology Research, Department of Biostatistics, Institute of Translational Medicine, University of Liverpool, Liverpool L69 3GS, UK

<sup>b</sup>School of Medicine, Dentistry and Biomedical Sciences, Centre for Public Health Institute for Health Sciences, Northern Ireland Methodology Hub, Queen's University Belfast, Belfast, UK

<sup>c</sup>Department of Family Medicine, SUNY Upstate Medical University, Syracuse, NY, USA

<sup>d</sup>Department of Informatics and Knowledge Management, Cochrane Central Executive, Freiburg, Germany

<sup>e</sup>Division of Molecular and Clinical Cancer Sciences, University of Manchester, Manchester, UK

Accepted 20 December 2017; Published online 28 December 2017

### Abstract

**Objectives:** There is increasing recognition that insufficient attention has been paid to the choice of outcomes measured in clinical trials. The lack of a standardized outcome classification system results in inconsistencies due to ambiguity and variation in how outcomes are described across different studies. Being able to classify by outcome would increase efficiency in searching sources such as clinical trial registries, patient registries, the Cochrane Database of Systematic Reviews, and the Core Outcome Measures in Effectiveness Trials (COMET) database of core outcome sets (COS), thus aiding knowledge discovery.

**Study Design and Setting:** A literature review was carried out to determine existing outcome classification systems, none of which were sufficiently comprehensive or granular for classification of all potential outcomes from clinical trials. A new taxonomy for outcome classification was developed, and as proof of principle, outcomes extracted from all published COS in the COMET database, selected Cochrane reviews, and clinical trial registry entries were classified using this new system.


# Outcomes taxonomy used to classify the studies

Table 1. Development of 38-category scale


Core area	Smith	Williamson/Clarke (initial)	Williamson/Clarke (revised)
Death	1: Mortality/survival	1: Mortality/survival	1: Mortality/survival
Physiological or clinical	2: Physiological/clinical 3: Infection 4: Pain	2: Physiological/clinical 3: Infection 4: Pain	2–24: <b>Physiological/clinical</b> 2: Blood and lymphatic system outcomes 3: Cardiac outcomes 4: Congenital, familial and genetic outcomes 5: Endocrine outcomes 6: Ear and labyrinth outcomes 7: Eye outcomes 8: Gastrointestinal outcomes 9: General outcomes 10: Hepatobiliary outcomes 11: Immune system outcomes 12: Infection and infestation outcomes 13: Injury and poisoning outcomes 14: Metabolism and nutrition outcomes 15: Musculoskeletal and connective tissue outcomes 16: Outcomes relating to neoplasms: benign, malignant and unspecified (including cysts and polyps) 17: Nervous system outcomes 18: Pregnancy, puerperium, and perinatal outcomes 19: Renal and urinary outcomes 20: Reproductive system and breast outcomes 21: Psychiatric outcomes 22: Respiratory, thoracic and mediastinal outcomes 23: Skin and subcutaneous tissue outcomes 24: Vascular outcomes
Life impact	5: Activities of daily living  6: Psychosocial 7: QoL  8: Compliance 9: Withdrawal from treatment/study 10: Satisfaction (patient, carer, health care provider)	5: Function - Physical - Social - Role 6: Psychosocial 7: Mental health 8: HRQL  9: Compliance (including withdrawal from treatment) 10: Satisfaction	<b>Functioning</b> 25: Physical functioning 26: Social functioning 27: Role functioning 28: Emotional functioning/well-being 29: Cognitive functioning 30: Global quality of life 31: Perceived health status 32: Delivery of care, including - Satisfaction/patient preference - Acceptability and availability - Adherence/compliance - Withdrawal from treatment - Appropriateness of treatment - Process, implementation, and service outcomes 33: Personal circumstances
Resource use	11: Medication 12: Economic 13: Hospital 14: Operative	11: Resource use - Economic - Hospital - Operative - Medication	<b>Resource use</b> 34: Economic 35: Hospital 36: Need for further intervention 37: Societal/carer burden
Adverse events	15: Adverse events/effects	12: Adverse events/effects	38: Adverse events/effects

Dodd, S., Clarke, M., Becker, L., Mavergames, C., Fish, R., & Williamson, P. R. (2018). A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery. *Journal of clinical epidemiology*, 96, 84-92.

# Primary outcomes- Frequency




# Primary outcomes - Disease Type



- 1. Mortality/survival outcome
- 3.1 Life impact- Physical functioning
- 3.3 Life impact- Role functioning
- 3.5 Life impact- Cognitive functioning
- 5. Perceived health status
- 7. Personal circumstances
- 9. Adverse events

- 2. Physiological/clinical
- 3.2 Life impact- Social functioning
- 3.4 Life impact- Emotional functioning/wellbeing
- 4. Global quality of life
- 6. Delivery of care
- 8. Resource use

# Primary outcomes - Statistical significance



# Content of Intervention

ORIGINAL ARTICLE

## The Behavior Change Technique Taxonomy (v1) of 93 Hierarchically Clustered Techniques: Building an International Consensus for the Reporting of Behavior Change Interventions

Susan Michie, DPhil, CPsychol · Michelle Richardson, PhD · Marie Johnston, PhD, CPsychol · Charles Abraham, DPhil, CPsychol · Jill Francis, PhD, CPsychol · Wendy Hardeman, PhD · Martin P. Eccles, MD · James Cane, PhD · Caroline E. Wood, PhD

Published online: 20 March 2013  
© The Society of Behavioral Medicine 2013

### Abstract

*Background* CONSORT guidelines call for precise reporting of behavior change interventions: we need rigorous methods of characterizing active content of interventions with precision and specificity.

*Objectives* The objective of this study is to develop an extensive, consensually agreed hierarchically structured taxonomy of techniques [behavior change techniques (BCTs)] used in behavior change interventions.

*Methods* In a Delphi-type exercise, 14 experts rated labels and definitions of 124 BCTs from six published classification systems. Another 18 experts grouped BCTs

according to similarity of active ingredients in an open-sort task. Inter-rater agreement amongst six researchers coding 85 intervention descriptions by BCTs was assessed.

*Results* This resulted in 93 BCTs clustered into 16 groups. Of the 26 BCTs occurring at least five times, 23 had adjusted kappas of 0.60 or above.


*Conclusions* “BCT taxonomy v1,” an extensive taxonomy of 93 consensually agreed, distinct BCTs, offers a step change as a method for specifying interventions, but we anticipate further development and evaluation based on international, interdisciplinary consensus.

Michie, S., Richardson, M., Johnston, M., Abraham, C., Francis, J., Hardeman, W., ... & Wood, C. E. (2013).

The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: building an international consensus for the reporting of behavior change interventions. *Annals of behavioral medicine*, 46(1), 81-95.



# Content of Intervention – BCT categories



# Risk of Bias (Revised Cochrane RoB tool)

	Randomization process	Assignment/adherence to intervention	Missing outcome	Measurement of outcome	Selection of the reported results
Quinn 2008	Yellow	Red	Red	Green	Green
Rossi 2010	Green	Green	Red	Green	Green
Charpentier 2011	Green	Green	Green	Green	Green
Quinn 2011	Green	Yellow	Red	Green	Green
Logan 2012	Green	Green	Green	Green	Yellow
Kirwan 2013	Yellow	Yellow	Red	Green	Green
Orsama 2013	Yellow	Red	Red	Green	Green
Rossi 2013	Green	Green	Yellow	Green	Green
Forjuoh 2014	Yellow	Yellow	Red	Green	Yellow
Torbjørnsen 2014	Green	Yellow	Green	Green	Green
Drion 2015	Green	Yellow	Green	Yellow	Yellow
Karhula 2015	Green	Yellow	Red	Yellow	Green
Wayne 2015	Green	Yellow	Red	Green	Green
Bee 2016	Green	Red	Red	Green	Green
Zhou 2016	Yellow	Red	Red	Green	Green
Baron 2017	Green	Yellow	Green	Green	Green
Goyal 2017	Yellow	Green	Green	Green	Green
Grady 2017	Yellow	Yellow	Red	Green	Green
Kleinman 2017	Green	Green	Red	Green	Green
Alanzi 2018	Yellow	Red	Green	Red	Yellow
Castensøe-Seidenfaden 2018	Yellow	Green	Green	Green	Green
Wang 2018	Green	Yellow	Green	Green	Yellow

# Conclusions and next steps

- ❑ A growing body of literature: more than 10,000 records identified through database searching and 131 full-text articles assessed for eligibility
  - However...few studies looking at “performance” of mobile health apps: only 57 studies testing the apps
  - Many studies focus on the previous steps in the design and use of the app without measuring the effects
- ❑ Mixed results in terms of statistical significance:
  - Could be due to?
    - Study design features (**small sample sizes** – 113 patients on average; **short duration of interventions** - almost 80% of studies under 6 months of follow-up (insufficient time horizon?); **traditional study design** – no adoption of innovative designs)
    - Type and content of the apps
    - Devices used
    - Attrition problems (constraints in demonstrating the long term usage of the apps by both patients and clinicians)

# Conclusions and next steps

- ❑ Primary Outcomes are mainly “clinical”: 36 studies show physiological primary outcomes
  - The real potential of apps with respect to NON clinical types of outcome still has to be proved
  
- ❑ As a results of these issues, generalizability of findings is weak and rarely addressed in the study discussion
  
- ❑ Coming up:
  - Analysis of app features that may impact on outcomes
  - Final drafting of the evaluation framework for mHealth apps
  - Testing and validation of the framework